



SK Life Science Appoints Dr. Sunita Misra, MD, PhD, as Vice President of Global Clinical Development and Acting Chief Medical Officer

Paramus, NJ, Apr. 8, 2024 – [SK Life Science, Inc.](#), a U.S. pharmaceutical company in pursuit of developing treatments that will change the future of central nervous system (CNS) disorders, appointed Dr. Sunita Misra, MD, PhD, as vice president of Global Clinical Development and acting Chief Medical Officer (CMO). Dr. Misra previously served as Senior Director of Clinical Development at SK Life Science.

In her new role, Dr. Misra will lead Clinical Development, Clinical Operations, Clinical Pharmacology, and Statistics & Data Management.

“We are thrilled to welcome Dr. Misra into this important new role, which will help us in the pursuit of developing treatments that will change the future of central nervous system disorders,” said Donghoon Lee, President and CEO of SK Life Science. “Her specialized expertise in pediatric, clinical neurophysiology, and epilepsy aligns perfectly with SK Life Science priorities in the CNS space. Dr. Misra’s deep knowledge of epilepsy allows her to keep a pulse on patient issues, which will help drive our pipeline forward and enable us to make a positive impact on the lives of more patients and caregivers affected by epilepsy.”

Dr. Misra is board certified by the American Board of Psychiatry and Neurology with Special Qualification in Child, Clinical Neurophysiology, and Epilepsy. Prior to SK Life Science, Dr. Misra participated in clinical development and medical affairs at Neurelis, Inc. where she worked on an ongoing Phase 1/2a study in pediatric epilepsy patients and co-developed clinical programs for pipeline programs such as IND filings. She is a pediatric neurology, epilepsy and neuroscience expert with experience in non-clinical and clinical aspects of channelopathy-related epilepsy.

Dr. Misra obtained her Bachelor of Science from Emory University, Doctor of Philosophy in the Department of Pharmacology from Vanderbilt University School of Medicine, and Doctor of Medicine from Vanderbilt University School of Medicine. From there, she completed a pediatric neurology residency and fellowships in clinical neurophysiology and epilepsy at Baylor College of Medicine/Texas Children’s Hospital. Dr. Misra then joined the faculty at Northwestern University as a physician-scientist seeing epilepsy patients at Ann & Robert H. Lurie Children’s Hospital of Chicago.

To learn more about Dr. Misra, please visit [here](#).

About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.

SK Biopharmaceuticals and its U.S. subsidiary SK Life Science are pharmaceutical companies focused on the research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin its expansion into oncology through research and development efforts. The companies have a pipeline of eight compounds in development in both CNS disorders and oncology. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website at www.skbp.com/eng and SK Life Science's website at www.SKLifeScienceInc.com.

Both SK Biopharmaceuticals and SK Life Science are part of SK Group, one of the largest conglomerates in Korea. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses.

Media Contact:

Dina Albanese
media@sklsi.com

###